SEC Tracker
Get the app
GPCR · XBRL financial data

Structure Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (GPCR's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development1820*21223333*43555969*67100
General and administrative911*11111314*13161518*2319
Total operating expenses2631*32334647*567074(24)*89119
Operating income (loss)(26)(31)*(32)(33)(46)(47)*(56)(70)(74)24*(89)(119)
Income tax expense (benefit)0(0)*0000*0000*00
Net income (loss)(24)(25)*(26)(26)(34)(36)*(47)(62)(66)33*(76)(106)
Earnings per share, basic USD per share(0.21)—(0.19)(0.18)(0.20)(0.21)*(0.27)(0.36)(0.37)0.17*(0.35)(0.49)
Earnings per share, diluted USD per share(0.21)—(0.19)(0.18)(0.20)(0.21)*(0.27)(0.36)(0.37)0.17*(0.35)(0.49)
Weighted average shares, basic millions of shares115—140148172172*172173175190*217218
Weighted average shares, diluted millions of shares115—140148172172*172173175190*217218

Balance sheet

CSV

Fiscal quarters (GPCR's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents5113098382172170152147103800316273
Short-term investments1553383395457437146856396966471,1421,070
Prepaid and other current assets56131188131315243229
Total current assets2104744499389248918507998141,5701,4911,372
Property and equipment, net233343435766
Right-of-use asset455444777666
Total assets2164824579479339038678168321,5841,5081,425
Accounts payable357288991814811
Total current liabilities202524233336363958635766
Lease liability, non-current344332554434
Total liabilities232927263638424462686171
Accumulated deficit(182)(207)(233)(259)(293)(329)(376)(438)(503)(470)(546)(652)
Total stockholders' equity1934534309218978658257727701,5161,4471,354
Total liabilities and equity2164824579479339038678168321,5841,5081,425
Common shares outstanding (cover page) millions of shares139140140172172172173173182213213214

Cash flows

CSV

Fiscal quarters (GPCR's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(24)(25)*(26)(26)(34)(36)*(47)(62)(66)33*(76)(106)
Stock-based compensation2*2*34*6*6*68*7*8*1213*
Net cash from operating activities(21)*(22)*(34)(26)*(20)*(36)*(52)(55)*(51)*(64)*15(120)*
Purchases of property and equipment1*1*00*1*0*00*2*1*1(0)*
Net cash from investing activities30*(181)*1(205)*(189)*33*3449*(49)*56*(497)75*
Proceeds from issuing common stock————0*0*——————
Net cash from financing activities0*282*1515*(1)*1*11*56*705*(2)2*
Net change in cash10*79*(32)284*(209)*(3)*(17)(5)*(44)*697*(483)(44)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Structure Therapeutics273not reported(120)*213.9M11.2 quarters 10-QJun 30, 2026
Wave Life Sciences19713(60)*197.2M7.4 quarters 10-QSep 30, 2026
Niagen Bioscience70272.6*79.2M— 10-QSep 30, 2026
Geron696010*644.2M— 10-QSep 30, 2026
Nurix Therapeutics720673616*109.2M— 10-QAug 31, 2026
Intellia Therapeutics1567.2(85)*140.4M4.9 quarters 10-QSep 30, 2026
Syndax Pharmaceuticals13683(27)*not reported11.9 quarters 10-QSep 30, 2026
Cogent Biosciences217not reported(81)*174.0M9.7 quarters 10-QSep 30, 2026
CorMedix25710286*77.9M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.